Herbert I Hurwitz
Overview
Explore the profile of Herbert I Hurwitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
5144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morse M, Crosby E, Halperin D, Uronis H, Hsu S, Hurwitz H, et al.
J Neuroendocrinol
. 2025 Feb;
:e13496.
PMID: 39933708
While performing a study of immune checkpoint blockade with the anti-PD-1 antibody pembrolizumab combined with the somatostatin analogue (SSA) lanreotide in patients with low- and intermediate-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs),...
2.
Liu Y, Li J, Lyu J, Howard L, Sibley A, Starr M, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Oct;
34(1):93-99.
PMID: 39400560
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation...
3.
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg J, et al.
Eur J Cancer
. 2024 Jun;
207:114160.
PMID: 38896997
Background: The liver is the most frequent site of metastases in colorectal cancer (CRC). This study aimed to assess the response rate and survival outcomes in metastatic CRC patients with...
4.
Yaung S, Ju C, Gattam S, Nicholas A, Sommer N, Bendell J, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565368
Sequencing circulating tumor DNA (ctDNA) from liquid biopsies may better assess tumor heterogeneity than limited sampling of tumor tissue. Here, we explore ctDNA-based heterogeneity and its correlation with treatment outcome...
5.
Mettu N, Ou F, Zemla T, Halfdanarson T, Lenz H, Breakstone R, et al.
JAMA Netw Open
. 2022 Feb;
5(2):e2149040.
PMID: 35179586
Importance: Cotargeting vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 may produce anticancer activity in refractory metastatic colorectal cancer (mCRC). The clinical benefit...
6.
Nixon A, Sibley A, Liu Y, Hatch A, Jiang C, Mulkey F, et al.
Clin Cancer Res
. 2021 Dec;
28(13):2779-2788.
PMID: 34965954
Purpose: CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in...
7.
Nixon A, Halabi S, Liu Y, Starr M, Brady J, Shterev I, et al.
Clin Cancer Res
. 2021 Dec;
28(13):2771-2778.
PMID: 34965953
Purpose: CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN). No difference...
8.
Strickler J, Rushing C, Uronis H, Morse M, Niedzwiecki D, Blobe G, et al.
Oncologist
. 2021 Jan;
26(6):465-e917.
PMID: 33469991
Lessons Learned: Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long-term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study...
9.
Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R, et al.
Cancer Treat Rev
. 2020 Apr;
86:102017.
PMID: 32335505
When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking...
10.
Ma X, Bendell J, Hurwitz H, Ju C, Lee J, Lovejoy A, et al.
Clin Cancer Res
. 2020 Mar;
26(15):4010-4017.
PMID: 32220893
Purpose: We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy. Experimental Design: The Sequencing Triplet With...